Cytokinetics Ownership | Who Owns Cytokinetics?
Cytokinetics Ownership Summary
Cytokinetics is owned by 114.72% institutional investors, 0.50% insiders. Blackrock is the largest institutional shareholder, holding 14.40% of CYTK shares. Vanguard Health Care Inv is the top mutual fund, with 3.45% of its assets in Cytokinetics shares.
CYTK Ownership Benchmark
Type | Name | % Inst | % Insiders | % Retail |
---|---|---|---|---|
Stock | Cytokinetics | 114.72% | 0.50% | -15.22% |
Sector | Healthcare Stocks | 88.01% | 8.90% | 3.09% |
Industry | Biotech Stocks | 109.70% | 8.77% | -18.47% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
Holder | Shares | % Holding | Value |
---|---|---|---|
Blackrock | 14.67M | 14.40% | $794.97M |
Blackrock funding, inc. /de | 15.47M | 13.14% | $727.68M |
Fmr | 11.52M | 11.31% | $624.32M |
Vanguard group | 11.44M | 11.22% | $619.69M |
T. rowe price investment management | 8.14M | 7.99% | $440.95M |
Wellington management group llp | 7.51M | 7.37% | $406.87M |
State street | 6.55M | 6.42% | $354.80M |
Geode capital management | 2.74M | 2.69% | $148.41M |
Rtw investments, lp | 2.72M | 2.67% | $147.43M |
Polar capital | 2.45M | 2.41% | $132.99M |
Top Institutional Shareholders by % of Total Assets
Holder | Shares | % Assets | Value |
---|---|---|---|
Rp management | 980.39K | 22.73% | $51.76M |
Superstring capital management lp | 187.63K | 12.81% | $10.17M |
Sarissa capital management lp | 1.11M | 10.15% | $60.14M |
Vestal point capital, lp | 2.08M | 8.38% | $112.42M |
Checkpoint capital | 190.00K | 6.21% | $10.29M |
Boxer capital | 2.10M | 5.99% | $113.78M |
Saturn v capital management | 272.04K | 5.57% | $14.74M |
Dafna capital management | 398.10K | 5.15% | $21.57M |
Integral health asset management | 1.00M | 5.15% | $54.18M |
Great point partners | 474.20K | 4.92% | $25.69M |
Top Buyers
Holder | Shares | % Assets | Change |
---|---|---|---|
Wellington management group llp | 7.51M | 0.07% | 3.53M |
T. rowe price investment management | 8.14M | 0.28% | 3.02M |
Blackrock | 14.67M | 0.02% | 2.26M |
State street | 6.55M | 0.02% | 2.03M |
Vanguard group | 11.44M | 0.01% | 1.44M |
Top Sellers
Holder | Shares | % Assets | Change |
---|---|---|---|
Darwin global management | - | - | -4.58M |
Marshall wace, llp | 1.68M | 0.12% | -878.64K |
Invesco | 495.40K | 0.01% | -822.14K |
Melqart asset management (uk) | - | - | -800.10K |
Avidity partners management lp | - | - | -600.00K |
New Positions
Holder | Shares | % Assets | Change | Value |
---|---|---|---|---|
Norges bank | 799.66K | 0.01% | 799.66K | $43.33M |
Massachusetts financial services co /ma/ | 276.07K | 0.00% | 276.07K | $14.96M |
Corebridge financial | 204.25K | 0.06% | 204.25K | $11.07M |
Opaleye management | 198.50K | 2.46% | 198.50K | $10.75M |
Granahan investment management | 136.88K | 0.30% | 136.88K | $7.42M |
Sold Out
Holder | Change |
---|---|
Financial gravity asset management | -2.00 |
Principal securities | -5.00 |
Institutional & family asset management | -7.00 |
Capital performance advisors llp | -8.00 |
Dinuzzo private wealth | -15.00 |
Institutional Ownership Trends
Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
---|---|---|---|---|---|---|---|---|---|---|
Sep 30, 2024 | 390 | 0.52% | 135,010,879 | -0.29% | 114 | 0.65% | 187 | -6.50% | 99 | -2.94% |
Jun 30, 2024 | 388 | -14.35% | 135,400,422 | 16.07% | 132 | 1.01% | 200 | -11.11% | 102 | -22.14% |
Mar 31, 2024 | 453 | 6.34% | 116,652,886 | 2.18% | 114 | 0.82% | 225 | 10.29% | 131 | 11.02% |
Dec 31, 2023 | 426 | 52.14% | 114,167,448 | 3.81% | 118 | 0.90% | 204 | 64.52% | 118 | 47.50% |
Sep 30, 2023 | 280 | 4.87% | 109,978,556 | 0.89% | 114 | 0.88% | 124 | -3.88% | 80 | - |
Top Mutual Funds Shareholders
Holder | Shares | % Holding | Change |
---|---|---|---|
Vanguard Health Care Inv | 4.07M | 3.45% | - |
iShares Core S&P Mid-Cap ETF | 3.85M | 3.26% | -1.00K |
Vanguard Total Stock Mkt Idx Inv | 3.72M | 3.16% | 3.79K |
iShares Russell 2000 ETF | 3.10M | 2.62% | -23.55K |
Vanguard Small Cap Index | 3.01M | 2.55% | 36.82K |
T. Rowe Price Mid-Cap Growth | 1.99M | 1.68% | - |
T. Rowe Price US Mid-Cap Growth Equity | 1.99M | 1.68% | -8.70K |
Vanguard Institutional Extnd Mkt Idx Tr | 1.78M | 1.51% | 19.66K |
SPDR® S&P Biotech ETF | 1.78M | 1.51% | -17.34K |
Vanguard Small Cap Growth Index Inv | 1.70M | 1.44% | 72.39K |
Recent Insider Transactions
Date | Name | Role | Activity | Value |
---|---|---|---|---|
Feb 04, 2025 | Malik Fady Ibraham | EVP Research & Development | Sell | $96.12K |
Jan 21, 2025 | Malik Fady Ibraham | EVP Research & Development | Sell | $91.84K |
Jan 07, 2025 | Malik Fady Ibraham | EVP Research & Development | Sell | $98.64K |
Dec 16, 2024 | WIERENGA WENDALL | - | Sell | $36.07K |
Dec 11, 2024 | HENDERSON JOHN T | - | Sell | $89.75K |
Insider Transactions Trends
Date | Buy | Sell |
---|---|---|
2025 Q1 | - | 3 |
2024 Q4 | - | 20 |
2024 Q3 | - | 25 |
2024 Q2 | - | 17 |
2024 Q1 | - | 12 |
CYTK Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools